BioSpace News Archive

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced enhancements to its Expanded Access and Right to Try programs.

A second Phase 3 trial evaluating Dupixent® in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease, met its primary and key secondary endpoints, showing it significantly reduced itch and skin lesions compared to placebo at 24 weeks in this investigational setting.

Regulated information – Inside information – UCB and Zogenix announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

Smith+Nephew, the global medical technology business, announces the acquisition of Engage Surgical, owner of the only cementless unicompartmental knee system commercially available in the US.

Engitix Ltd, a biopharmaceutical company with a pioneering and proprietary human extracellular matrix drug target discovery platform announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 for the treatment of hepatocellular carcinoma, to be presented at the ASCO GI Cancers Symposium on January 20-22, 2022.

BioInvent International AB announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma.

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced the appointment of Janis M. Taube, M.D., M.Sc., a leading pathologist and expert on immunotherapy research, to its Scientific Advisory Board.

The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management.

Eluminex Biosciences announced today that it has acquired certain assets and the related global development and commercialization rights for a novel oral therapy, zuretinol acetate (zuretinol), from Retinagenix Holdings, LLC (Retinagenix).